Impact of PET-FDG in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary.
We carried out a study to evaluate the contribution of positron emission tomography with (18)F-fluorodeoxyglucose (PET-FDG) in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary. PET-FDG was prospectively performed in 51 patients. The PET-FDG data were confirmed histologically or by a follow-up on average at 13 months. PET-FDG identified the primary in 24 percent of cases, and detected the presence of additional metastases in 41 percent of cases. PET-FDG led to a therapeutic modification for 12 patients (24 percent). Furthermore, the therapeutic impact seems more marked in localized forms than in the multifocal. This broad exploratory study confirms the important role of PET-FDG in the diagnosis and therapeutic management of patients with metastases of unknown primary.
Garin
Etienne
E
UPRES EA 3890/Department of Medical Imagery, Centre Eugène Marquis, Rennes, France. etienne.garin@univ-rennesl.fr
Prigent-Lejeune
Florence
F
Lesimple
Thierry
T
Barge
Marie-Luce
ML
Rousseau
Caroline
C
Devillers
Anne
A
Bouriel
Catherine
C
Habiba
Mesbah T
MT
Bernard
Anne-Marie
AM
Bridji
Boumédienne
B
Resche
Isabelle
I
D004268:DNA-Binding Proteins / Q000032:analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed; D014157:Transcription Factors
D004268:DNA-Binding Proteins; C504003:TTF1 protein, human; D014157:Transcription Factors; D019788:Fluorodeoxyglucose F18